Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
Authors
Keywords
-
Journal
Molecular Oncology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-01-31
DOI
10.1002/1878-0261.12645
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
- (2019) Tri Le et al. Cancers
- Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
- (2019) Ayesha Murtuza et al. CANCER RESEARCH
- Honokiol Induces Autophagic Apoptosis in Neuroblastoma Cells through a P53-Dependent Pathway
- (2019) Ming-Chung Lin et al. AMERICAN JOURNAL OF CHINESE MEDICINE
- Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets
- (2019) Kishore Banik et al. PHARMACOLOGICAL RESEARCH
- Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer
- (2019) Fei Cao et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib
- (2019) Yiting Li et al. CANCER
- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Toxicology of Magnolol and Honokiol
- (2018) Andrea Sarrica et al. PLANTA MEDICA
- BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review
- (2018) Xuanzong Li et al. Targeted Oncology
- Mechanisms and Therapy for Cancer Metastasis to the Brain
- (2018) Federica Franchino et al. Frontiers in Oncology
- Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy
- (2018) Guoqing Qian et al. CANCER LETTERS
- Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3
- (2017) S Sengupta et al. ONCOGENE
- Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
- (2016) Puyu Shi et al. CANCER LETTERS
- Honokiol Decreases Lung Cancer Metastasis through Inhibition of the STAT3 Signaling Pathway
- (2016) Jing Pan et al. Cancer Prevention Research
- Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor–stromal cross-talk
- (2016) Courey Averett et al. CARCINOGENESIS
- Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer
- (2016) Azusa Tanimoto et al. CLINICAL CANCER RESEARCH
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
- (2015) M. J. Niederst et al. CLINICAL CANCER RESEARCH
- Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
- (2015) Michael Juchum et al. DRUG RESISTANCE UPDATES
- mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation
- (2015) Junghui Koo et al. MOLECULAR AND CELLULAR BIOLOGY
- Overcoming Resistance to Targeted Therapy for Lung Cancer
- (2015) Ramaswamy Govindan NEW ENGLAND JOURNAL OF MEDICINE
- Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
- (2015) Alfredo Tartarone et al. Therapeutic Advances in Respiratory Disease
- The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis
- (2013) Hui Ren et al. CANCER LETTERS
- Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins
- (2013) J. Remon et al. CANCER TREATMENT REVIEWS
- Neuro-Modulating Effects of Honokiol: A Review
- (2013) Anna Woodbury et al. Frontiers in Neurology
- Thr 163 Phosphorylation Causes Mcl-1 Stabilization when Degradation Is Independent of the Adjacent GSK3-Targeted Phosphodegron, Promoting Drug Resistance in Cancer
- (2012) Shanna K. Nifoussi et al. PLoS One
- Therapeutic applications of compounds in the Magnolia family
- (2011) Young-Jung Lee et al. PHARMACOLOGY & THERAPEUTICS
- Honokiol Crosses BBB and BCSFB, and Inhibits Brain Tumor Growth in Rat 9L Intracerebral Gliosarcoma Model and Human U251 Xenograft Glioma Model
- (2011) Xianhuo Wang et al. PLoS One
- The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis
- (2008) S. M. Raja et al. MOLECULAR CANCER THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started